Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Starting young: Aimmune begins new trial treating peanut allergy in toddlers

Aimmune’s newly begun POSEIDON trial and DBV’s ongoing EPITOPE trial exploring the use of peanut immunotherapy in children 1–3 years old will have a powerful effect on shaping the growing peanut allergy market.

  • peanut allergy

Go Top